<!DOCTYPE html>
<html lang="en">
<head>

<title>GnRH Antagonists Abarelix and Degarelix for Metastatic Prostate Cancer </title>
  <meta charset="utf-8">
  
  <link href="urology.css" rel="stylesheet">

<meta name="keywords" content="gnrh antagonists, degarelix, abarelix" >
<meta name="description" content="Pharmacological profile of GnRH antagonists abarelix and degarelix to treat advanced prostate cancer...., from the online textbook of urology by D. Manski" >
<meta name="author" content="Dr. med. Dirk Manski" >
<meta name="copyright" content="Dirk Manski" >
<meta name="robots" content="index">
<meta name="robots" content="follow">
<meta name="viewport" content="width=device-width, initial-scale=1">
<script type="text/javascript" src="https://steadyhq.com/widget_loader/d07e8b63-2cb6-4caa-8cd8-ac224b34b49f"></script></head>

<body><script src="https://consent.cookiefirst.com/banner.js" data-cookiefirst-key="37f6f6c6-5bff-4142-be7d-7a354b5345de"></script>
<header>
    <a class="ribbon" tabindex="-1" title="back to start!" href="http://www.urology-textbook.com/index.html">
	   <h5 id="logo">urology-textbook.com</h5>
       <p>Dr. med. Dirk Manski</p>
    </a>  
</header>
<main>
<nav id="navigation">
<ul>
<li><a href="http://www.urology-textbook.com/index.html">Start</a></li>
<li><a href="http://www.urology-textbook.com/anatomy.html">Anatomy</a></li>
<li><a href="http://www.urology-textbook.com/signs-and-symptoms.html">Signs and Symptoms</a></li>
<li><a href="http://www.urology-textbook.com/examinations.html">Examinations</a></li>
<li><a href="http://www.urology-textbook.com/surgical-management.html">Surgical Management</a></li>
<li><a href="http://www.urology-textbook.com/pharmacology.html">Pharmacology</a></li>
<li><a href="http://www.urology-textbook.com/kidneys.html">Kidneys</a></li>
<li><a href="http://www.urology-textbook.com/ureters.html">Ureters</a></li>
<li><a href="http://www.urology-textbook.com/bladder.html">Bladder</a></li>
<li><a href="http://www.urology-textbook.com/prostate.html">Prostate</a></li>
<li><a href="http://www.urology-textbook.com/urethra.html">Urethra</a></li>
<li><a href="http://www.urology-textbook.com/penis.html">Penis</a></li>
<li><a href="http://www.urology-textbook.com/testes.html">Testes</a></li>
<li><a href="http://www.urology-textbook.com/adrenal-glands.html">Adrenal Glands</a></li>
<li><a href="http://www.urology-textbook.com/common-diseases.html">Common Diseases</a></li>
<li><a href="http://www.urology-textbook.com/urologic-surgery.html">Urologic Surgery</a></li>
<li><a href="http://www.urology-textbook.com/index-urology.html">Index</a></li>
<li><a href="http://www.urology-textbook.com/medical-abbreviations.html">Abbreviations</a></li>
<li><a href="http://www.urology-textbook.com/urology-news.html">News</a></li>
<li><a href="http://www.urology-textbook.com/links.html">Links</a></li>
</ul>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<script type="steady-switch" data-when="no-subscription"><!-- 
<ins class="adsbygoogle"
     style="display:block"
     data-ad-client="ca-pub-9284927104423861"
     data-ad-slot="3282433998"
     data-ad-format="auto"
     data-full-width-responsive="true"></ins>
<script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>
--></script>
</nav>
<article>
<br>
<script type="steady-switch" data-when="no-subscription"><!-- 
<ins class="adsbygoogle"
     style="display:block"
     data-ad-client="ca-pub-9284927104423861"
     data-ad-slot="8643406037"
     data-ad-format="auto"
     data-full-width-responsive="true"></ins>
<script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>
--></script>
<br>
<p id="brotkrumen">&nbsp;You are here: <a href="http://www.urology-textbook.com/index.html">Urology Textbook</a> &gt; <a href="http://www.urology-textbook.com/pharmacology.html">Drugs in Urology</a> &gt; GnRH antagonists</p><!-- Main content -->
<h1>GnRH Antagonists Abarelix and Degarelix</h1>
<p>Currently approved GnRH antagonists for the treatment of advanced <a href="http://www.urology-textbook.com/prostate-cancer.html">prostate cancer</a> are <i>abarelix</i> (approved in Germany since 2008) and <i>degarelix</i> (approved in Germany 2009). Other GnRH antagonists are in development or are being used for fertility treatment (cetrorelix and ganirelix) (Debruyne et al, 2006).</p>

<h2>Mechanism of Action of GnRH Antagonists </h2> 
<p>Degarelix and abarelix are gonadotropin-releasing hormone antagonists, they stop secretion of <a href="http://www.urology-textbook.com/male-hormones-testosterone.html#androgens">LH and FSH</a> with a dramatic reduction of the <a href="http://www.urology-textbook.com/testosterone-serum-test.html">testosterone concentration</a>. </p><h2>Indications for GnRH antagonists</h2> 
<p>Abarelix and degarelix are used for <a href="http://www.urology-textbook.com/prostate-cancer-hormonal-treatment.html">hormone therapy of advanced or metastatic prostate cancer</a>, as an alternative to surgical castration or treatment with GnRH analogues. The advantage of GnRH antagonists is an immediate, fast and reliable decrease in serum testosterone concentration (usually below 0.2 ng/ml). A short-term increase in testosterone, which is typical for GnRH analogues, does not occur. Thus, GnRH antagonists are ideal in patients who are at risk by a testosterone surge (e.g. symptomatic bone metastases with spinal cord compression). Disadvantages of GnRH antagonists is the limited data on long term safety, particularly concerning the immediate type allergic reaction or the cardiac side effects. </p><h2>Pharmacokinetics of Abarelix and Degarelix</h2>

<h3>Abarelix: </h3>
<p>Abarelix is a synthetic decapeptide, which is administered as an intramuscular depot preparation. After treatment with abarelix, 94% of the patients reach castration level (&lt;0.5 ng/ml testosterone) within 4 weeks (<a HREF="#Trachtenberg2002">Trachtenberg et al, 2002</a>) . </p>
 
<h3>Degarelix: </h3>
<p>Degarelix is a synthetic peptide derivative of the natural GnRH, which is administed as a subcutaneous depot preparation. After treatment with degarelix, 99% of patients reach castration level within 7 days (<a HREF="#Klotz2008">Klotz et al, 2008</a>). </p>

<h2>Side Effects of GnRH Antagonists </h2>

<p>Abarelix and Degarelix cause a pronounced hypogonadism with the following side effects (similar to GnRH agonist or surgical castration): osteoporosis, hot flashes, decreased libido, <a href="http://www.urology-textbook.com/erectile-dysfunction.html">loss of erectile function</a>, impaired memory function, physical weakness, fatigue, depression, increased cardiovascular risk, elevated transaminases and <a href="http://www.urology-textbook.com/gynecomastia.html">gynecomastia</a>. </p><h3>Specific side effects of abarelix:</h3>

<ul title="side effects of abarelix">
<li>Systemic allergic reactions of the immediate-type: urticaria, pruritus, hypotension and syncope. The frequency of severe allergic reaction after a year of therapy with abarelix is 1.7%. Due to the possible severity of allergic reactions, the administration of abarelix is controversial.
</li>
</ul>

<h3>Specific side effects of degarelix: </h3>

<ul title="side effects of degarelix">
<li>Allergic reactions: degarelix is reported to cause significantly less allergic side effects compared to abarelix.
</li>
</ul><h2>Contraindications of Degarelix and Abarelix</h2>

<ul title="contraindications of degarelix and abarelix">
<li>GnRH antagonists are contraindicated (and useless) after surgical castration. </li>
<li>Children and Women</li>
<li>Severe allergic reactions after injection. </li>
<li>QT interval exceeding 450 msec. </li>
<li>Persistently increased transaminase concentrations (twice of the standard value).</li>
<li>Hepatic and renal insufficiency. </li>
</ul><h2>Dosage of Abarelix: </h2> 
<p>Intramuscular injection of 100 mg abarelix on days 1, 15, 29 and every 4 weeks thereafter. Monitoring of therapy success: testosterone and <a href="http://www.urology-textbook.com/psa-test.html">PSA concentration</a>. </p>
<h2>Dosage of Degarelix: </h2> 
<p>Subcutaneous injection of 2 Ã— 120 mg degarelix at day 1 (two injections), followed by 80 mg s.c. every 4 weeks. Monitoring of therapy sucess: testosterone and PSA concentration.</p>
<br>
<br>

<table  id="navigation_unten">
<tr>
 
<td><a href="http://www.urology-textbook.com/gnrh-agonists.html">GnRH agonists</a></td>
<td><a class="nav4" href="http://www.urology-textbook.com/index-urology.html">Index</a></td>
<td><a class="nav3" href="http://www.urology-textbook.com/abiraterone.html">Abiraterone</a></td>
 
</tr>
</table>
<br><br>

<script type="steady-switch" data-when="no-subscription"><!-- 
<ins class="adsbygoogle"
     style="display:block"
     data-ad-client="ca-pub-9284927104423861"
     data-ad-slot="8643406037"
     data-ad-format="auto"
     data-full-width-responsive="true"></ins>
<script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>
--></script>
<br>
<br>
Index: <a href="http://www.urology-textbook.com/index-urology-a.html">1&ndash;9</a> <a href="http://www.urology-textbook.com/index-urology-a.html">A</a> <a href="http://www.urology-textbook.com/index-urology-b.html">B</a> <a href="http://www.urology-textbook.com/index-urology-c.html">C</a> <a href="http://www.urology-textbook.com/index-urology-d.html">D</a> <a href="http://www.urology-textbook.com/index-urology-e.html">E</a> <a href="http://www.urology-textbook.com/index-urology-f.html">F</a> <a href="http://www.urology-textbook.com/index-urology-g.html">G</a> <a href="http://www.urology-textbook.com/index-urology-h.html">H</a> <a href="http://www.urology-textbook.com/index-urology-i.html">I</a> <a href="http://www.urology-textbook.com/index-urology-j.html">J</a> <a href="http://www.urology-textbook.com/index-urology-k.html">K</a> <a href="http://www.urology-textbook.com/index-urology-l.html">L</a> <a href="http://www.urology-textbook.com/index-urology-m.html">M</a> <a href="http://www.urology-textbook.com/index-urology-n.html">N</a> <a href="http://www.urology-textbook.com/index-urology-o.html">O</a> <a href="http://www.urology-textbook.com/index-urology-p.html">P</a> <a href="http://www.urology-textbook.com/index-urology-q.html">Q</a> <a href="http://www.urology-textbook.com/index-urology-r.html">R</a> <a href="http://www.urology-textbook.com/index-urology-s.html">S</a> <a href="http://www.urology-textbook.com/index-urology-t.html">T</a> <a href="http://www.urology-textbook.com/index-urology-u.html">U</a> <a href="http://www.urology-textbook.com/index-urology-v.html">V</a> <a href="http://www.urology-textbook.com/index-urology-w.html">W</a> <a href="http://www.urology-textbook.com/index-urology-xyz.html">X Y Z</a> 

<br>
<br>
<hr>
<br>
  
<br>
<hr><h3>References</h3>

<dl>
<br>
<p>
<dt><a NAME="Debruyne2006">
Debruyne u.a. 2006 D<SMALL>EBRUYNE</SMALL>, Frans&nbsp;; B<SMALL>HAT</SMALL>,
  Gajanan&nbsp;; G<SMALL>ARNICK</SMALL>, Marc&nbsp;B.:
</a>
<dd> Abarelix for injectable suspension: first-in-class
  gonadotropin-releasing hormone antagonist for prostate cancer.
<br> In: <I>Future Oncol</I>
<br> 2 (2006), Dec, Nr.&nbsp;6, S.&nbsp;677&ndash;696. -
<br> URL <TT>http://dx.doi.org/10.2217/14796694.2.6.677</TT>
<br>

<br>
<p>
<dt><a NAME="Klotz2008">
Klotz u.a. 2008 K<SMALL>LOTZ</SMALL>, L.&nbsp;; B<SMALL>OCCON-</SMALL>G<SMALL>IBOD</SMALL>, L.&nbsp;;
  S<SMALL>HORE</SMALL>, N.&nbsp;D.&nbsp;; A<SMALL>NDREOU</SMALL>, C.&nbsp;; P<SMALL>ERSSON</SMALL>, B.-E.&nbsp;;
  C<SMALL>ANTOR</SMALL>, P.&nbsp;; J<SMALL>ENSEN</SMALL>, J.-K.&nbsp;; O<SMALL>LESEN</SMALL>, T.&nbsp;K.&nbsp;;
  S<SMALL>CHR&ouml;DER</SMALL>, F.&nbsp;H.:
</a>
<dd> The efficacy and safety of degarelix: a 12-month, comparative,
  randomized, open-label, parallel-group phase III study in patients with
  prostate cancer.
<br> In: <I>BJU Int</I>
<br> 102 (2008), Dec, Nr.&nbsp;11, S.&nbsp;1531&ndash;1538. -
<br> URL <TT>http://dx.doi.org/10.1111/j.1464&ndash;410X.2008.08183.x</TT>
<br>

<br>
<p>
<dt><a NAME="Trachtenberg2002">
Trachtenberg u.a. 2002 T<SMALL>RACHTENBERG</SMALL>, J.&nbsp;;
  G<SMALL>ITTLEMAN</SMALL>, M.&nbsp;; S<SMALL>TEIDLE</SMALL>, C&nbsp;; B<SMALL>ARZELL</SMALL>, W.&nbsp;;
  F<SMALL>RIEDEL</SMALL>, W.&nbsp;; P<SMALL>ESSIS</SMALL>, D.&nbsp;; F<SMALL>OTHERINGHAM</SMALL>, N.&nbsp;;
  C<SMALL>AMPION</SMALL>, M.&nbsp;; G<SMALL>ARNICK</SMALL>, M.&nbsp;B.&nbsp;; G<SMALL>ROUP</SMALL>, Abarelix&nbsp;S.:
</a>
<dd> A phase 3, multicenter, open label, randomized st.udy of abarelix
  versus leuprolide plus daily antiandrogen in men with prostate cancer.
<br> In: <I>J Urol</I>
<br> 167 (2002), Apr, Nr.&nbsp;4, S.&nbsp;1670&ndash;1674

</dl>
<br>
<br>
<p><img src="deutsch.gif">&nbsp; Deutsche Version: <a href="https://www.urologielehrbuch.de/lhrh-antagonisten.html">GnRH Antagonisten</a></p>
</article>
</main>
<footer class="grid">
    <ul id="footer-nav">
    		<li>Copyright by Dr. med. Dirk Manski </li>
		<li><a href="http://www.urology-textbook.com/privacy-policy.html">Privacy policy</a></li>
		<li><a href="http://www.urology-textbook.com/disclaimer.html">Disclaimer</a></li>
	</ul><script defer src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
</footer>
</body>
</html>
